In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Conjugate Pegvisomant | Natural peptide HGH (somatotropin) | |
|---|---|---|---|
| Identity | |||
| Kind | Conjugate | Natural peptide | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 299 | 1,108 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 12 (12 in people) | 110 (108 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 37 · 1 active4 more mention it but do not test it | 358 · 32 active72 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Somavert says: “Acromegaly in patients with an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Pegvisomant | HGH (somatotropin) |
|---|---|---|
| Growth hormone and IGF-1Metabolic and weight | 13111021 | 1069115 |
| Bone and joint |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Genotropin says: “Replacement in adults with adult-onset or childhood-onset GHD”
1147 |
12611511 |
| Glycemic controlMetabolic and weight | 2626 | 8585 |
|---|
| LipidsMusculoskeletal | 1919 | 7373 |
|---|
| Adverse eventsWhole body | 1212 | 60582 |
|---|
| Exercise and physical functionMusculoskeletal | 33 | 4141 |
|---|
| Body weightMetabolic and weight | 11 | 46415 |
|---|
| Protein and amino acid metabolismMetabolic and weight | 11 | 3131 |
|---|
| Receptor activity and mechanismPharmacology | 17197 | 2626 |
|---|
| Quality of lifeWhole body | 77 | 2121 |
|---|
| PharmacokineticsPharmacology | 1313 | 23320 |
|---|
| Sex hormones and fertilityReproductive and sexual health | 22 | 1313 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Pegvisomant differs from Human growth hormone at 9 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Pegvisomant | HGH (somatotropin) |
|---|---|---|
| Bone and jointMusculoskeletalCompared as: value in the arm that got the peptide, in nmol/l | −2.2 nmol/l Osteocalcin change Placebo: 0.01 nmol/l Dose studied: 10, 15 or 20 mg12 weeksn = 272002 | No comparable result 29 randomized-trial results measure it in another way or another unit. |
| Inflammation markersImmune and inflammationCompared as: value in the arm that got the peptide, in mg/liter | 13.7 mg/liter CRP · pegvisomant 20 mg Placebo: 0.5 mg/liter Dose studied: 20 mg daily12 weeksn = 262002 | |
| Growth hormone and IGF-1Endocrine and hormonesCompared as: difference from placebo, in % | −34% Total IGF-I reduction · Shown as a change. The study reports a total igf-i reduction of this size. Dose studied: 1 mg/kg, single injectionn = 162002 | |
| LipidsMetabolic and weightCompared as: value in the arm that got the peptide, in micromol/liter | 1074 micromol/liter Free fatty acids Saline: 1226 micromol/liter n = 102009 | No comparable result 6 randomized-trial results measure it in another way or another unit. |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | 79.1% Treatment-emergent adverse events Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2242022 |
−2.2 nmol/l
Osteocalcin change
Placebo: 0.01 nmol/l
Dose studied: 10, 15 or 20 mg12 weeksn = 272002
No comparable result
29 randomized-trial results measure it in another way or another unit.
No comparable result
1 randomized-trial result measure it in another way or another unit.
No comparable result
27 randomized-trial results measure it in another way or another unit.
13.7 mg/liter
CRP · pegvisomant 20 mg
Placebo: 0.5 mg/liter
Dose studied: 20 mg daily12 weeksn = 262002
No comparable result
1 randomized-trial result measure it in another way or another unit.
−34%
Total IGF-I reduction · Shown as a change. The study reports a total igf-i reduction of this size.
Dose studied: 1 mg/kg, single injectionn = 162002
No comparable result
27 randomized-trial results measure it in another way or another unit.
1074 micromol/liter
Free fatty acids
Saline: 1226 micromol/liter
n = 102009
No comparable result
6 randomized-trial results measure it in another way or another unit.
No comparable result
1 randomized-trial result measure it in another way or another unit.
79.1%
Treatment-emergent adverse events
Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2242022
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 37 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Ipsen125 participantsOct 2006 to Oct 2008
Acromegaly
Novartis Pharmaceuticals70 participantsSept 2006 to Nov 2009
Acromegaly
Vanderbilt University44 participantsJan 2013 to May 2017
Obesity
4 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 358 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S712 participantsJul 2007 to Dec 2008
Chronic Kidney Disease · End-Stage Renal Disease
EMD Serono326 participants28 May 2004 to 28 Sept 2005
HIV Infections · Lipodystrophy
Pfizer316 participantsDec 2006 to Aug 2012
Idiopathic Short Stature
72 more mention it but do not test it. They only measure it or name it in their text.